MA48475A - Procédés de fabrication de niraparib - Google Patents
Procédés de fabrication de niraparibInfo
- Publication number
- MA48475A MA48475A MA048475A MA48475A MA48475A MA 48475 A MA48475 A MA 48475A MA 048475 A MA048475 A MA 048475A MA 48475 A MA48475 A MA 48475A MA 48475 A MA48475 A MA 48475A
- Authority
- MA
- Morocco
- Prior art keywords
- niraparib
- manufacturing processes
- processes
- manufacturing
- niraparib manufacturing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 229950011068 niraparib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762489387P | 2017-04-24 | 2017-04-24 | |
| US201762489415P | 2017-04-24 | 2017-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48475A true MA48475A (fr) | 2020-03-04 |
Family
ID=63919973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048475A MA48475A (fr) | 2017-04-24 | 2018-04-24 | Procédés de fabrication de niraparib |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11161834B2 (fr) |
| EP (1) | EP3615513B1 (fr) |
| JP (1) | JP7179014B2 (fr) |
| KR (1) | KR102582624B1 (fr) |
| CN (2) | CN118271233A (fr) |
| AU (2) | AU2018258274C1 (fr) |
| BR (1) | BR112019022320A2 (fr) |
| CA (1) | CA3060715A1 (fr) |
| ES (1) | ES2926255T3 (fr) |
| IL (1) | IL270068B (fr) |
| MA (1) | MA48475A (fr) |
| SG (1) | SG11201909807TA (fr) |
| TW (1) | TWI783993B (fr) |
| WO (1) | WO2018200517A1 (fr) |
| ZA (1) | ZA201906944B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
| WO2018200517A1 (fr) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Procédés de fabrication de niraparib |
| EP3624850A1 (fr) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Polythérapies pour le traitement du cancer |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| MA50409A (fr) | 2017-09-30 | 2020-08-26 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| CN112300074B (zh) * | 2019-08-02 | 2023-12-29 | 北京盈科瑞创新药物研究有限公司 | 一种吲唑甲酰胺类化合物及其制备方法和应用 |
| WO2023159066A1 (fr) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Utilisation de niraparib pour le traitement du cancer du cerveau |
| WO2024142096A1 (fr) * | 2022-12-29 | 2024-07-04 | Dr. Reddy’S Laboratories Limited | Procédé de préparation de tosylate de niraparib et de ses intermédiaires |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| JP4213771B2 (ja) | 1997-04-23 | 2009-01-21 | 株式会社カネカ | 光学活性アミノ化合物の製造方法 |
| IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1272967A2 (fr) | 2000-03-30 | 2003-01-08 | Maxygen, Inc. | Selection de sites de recombinaison par enjambement in silico |
| WO2002085838A1 (fr) | 2001-04-24 | 2002-10-31 | Massachusetts Institute Of Technology | Formation par catalyse de cuivre de liaisons carbone-heteroatome et carbone-carbone |
| US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| AR051823A1 (es) | 2004-09-29 | 2007-02-14 | Mitsubishi Pharma Corp | Derivados de piridinil-pirimidonas |
| JP4611441B2 (ja) | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
| JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
| GEP20115337B (en) * | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| WO2008108998A2 (fr) | 2007-03-02 | 2008-09-12 | Richmond Chemical Corporation | Procédé pour augmenter le rendement et améliorer la purification de produits provenant de réactions avec une transaminase |
| AR065804A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US20100222326A1 (en) | 2007-04-27 | 2010-09-02 | Ucb Pharma, S.A. | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders |
| AU2009203598B2 (en) | 2008-01-08 | 2013-09-26 | Merck Sharp & Dohme Llc | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide |
| US8293507B2 (en) | 2009-02-26 | 2012-10-23 | Codexis, Inc. | Transaminase biocatalysts |
| JP2010269667A (ja) | 2009-05-20 | 2010-12-02 | Alps Electric Co Ltd | 多回転角度検出装置 |
| EP2606139B1 (fr) | 2010-08-16 | 2015-07-15 | Codexis, Inc. | Biocatalyseurs et procédés de synthèse de (1r,2r)-2-(3,4-diméthoxyphényléthoxy)cyclohexanamine |
| BR112013013417A2 (pt) | 2010-11-30 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal |
| DK2673260T3 (en) | 2011-02-08 | 2016-10-10 | Pfizer | Glucagonreceptormodulator |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| PT2928865T (pt) | 2012-12-07 | 2018-06-11 | Merck Sharp & Dohme | Processo de transaminação biocatalítica |
| WO2014088983A1 (fr) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Arylation n-2 régiosélective d'indazoles |
| EP3230472A4 (fr) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Méthodes et matériaux permettant de prédire une réaction au niraparib |
| FI3478286T3 (fi) | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| CN106496187A (zh) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| CN106432056A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法 |
| CN106432055A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
| EP3606523A1 (fr) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Formulations de niraparib |
| WO2018200517A1 (fr) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Procédés de fabrication de niraparib |
| CN110831580A (zh) | 2017-05-09 | 2020-02-21 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| EP3624850A1 (fr) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Polythérapies pour le traitement du cancer |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| MA50409A (fr) | 2017-09-30 | 2020-08-26 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| WO2019133697A1 (fr) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Méthodes de traitement du cancer |
| WO2019152989A1 (fr) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Formulations pédiatriques de niraparib et procédés de traitement pédiatrique |
-
2018
- 2018-04-24 WO PCT/US2018/029131 patent/WO2018200517A1/fr unknown
- 2018-04-24 AU AU2018258274A patent/AU2018258274C1/en active Active
- 2018-04-24 TW TW107113922A patent/TWI783993B/zh active
- 2018-04-24 JP JP2019557567A patent/JP7179014B2/ja active Active
- 2018-04-24 CA CA3060715A patent/CA3060715A1/fr active Pending
- 2018-04-24 CN CN202410234039.3A patent/CN118271233A/zh active Pending
- 2018-04-24 BR BR112019022320-7A patent/BR112019022320A2/pt unknown
- 2018-04-24 CN CN201880040321.0A patent/CN110753684A/zh active Pending
- 2018-04-24 KR KR1020197034673A patent/KR102582624B1/ko active IP Right Grant
- 2018-04-24 IL IL270068A patent/IL270068B/en unknown
- 2018-04-24 MA MA048475A patent/MA48475A/fr unknown
- 2018-04-24 US US16/608,059 patent/US11161834B2/en active Active
- 2018-04-24 EP EP18790167.3A patent/EP3615513B1/fr active Active
- 2018-04-24 ES ES18790167T patent/ES2926255T3/es active Active
- 2018-04-24 SG SG11201909807T patent/SG11201909807TA/en unknown
-
2019
- 2019-10-22 ZA ZA2019/06944A patent/ZA201906944B/en unknown
-
2021
- 2021-08-09 AU AU2021215116A patent/AU2021215116B2/en active Active
- 2021-10-29 US US17/452,928 patent/US11629137B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI783993B (zh) | 2022-11-21 |
| IL270068B (en) | 2022-06-01 |
| TW201841889A (zh) | 2018-12-01 |
| CA3060715A1 (fr) | 2018-11-01 |
| AU2018258274A1 (en) | 2019-11-14 |
| AU2018258274B2 (en) | 2021-05-13 |
| AU2021215116A1 (en) | 2021-08-26 |
| US20220041575A1 (en) | 2022-02-10 |
| WO2018200517A1 (fr) | 2018-11-01 |
| KR20200021456A (ko) | 2020-02-28 |
| US11161834B2 (en) | 2021-11-02 |
| SG11201909807TA (en) | 2019-11-28 |
| JP7179014B2 (ja) | 2022-11-28 |
| EP3615513A1 (fr) | 2020-03-04 |
| US20200055837A1 (en) | 2020-02-20 |
| US11629137B2 (en) | 2023-04-18 |
| ZA201906944B (en) | 2023-03-29 |
| EP3615513A4 (fr) | 2020-12-09 |
| CN118271233A (zh) | 2024-07-02 |
| AU2021215116B2 (en) | 2022-12-01 |
| JP2020517668A (ja) | 2020-06-18 |
| AU2018258274C1 (en) | 2021-12-02 |
| ES2926255T3 (es) | 2022-10-24 |
| CN110753684A (zh) | 2020-02-04 |
| KR102582624B1 (ko) | 2023-09-22 |
| EP3615513B1 (fr) | 2022-07-20 |
| BR112019022320A2 (pt) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51792A (fr) | Procédés de fabrication de lymphocytes t | |
| DE102016200026B8 (de) | Wafer-Herstellungsverfahren | |
| MA43711A (fr) | Procédés de production de l-glufosinate | |
| MA48475A (fr) | Procédés de fabrication de niraparib | |
| FR3046093B1 (fr) | Atelier de fabrication additive | |
| GB201718897D0 (en) | Superconductor-semiconductor fabrication | |
| DK3310494T3 (da) | Robotkøretøj | |
| DK3481569T3 (da) | Flerkammeraflejringsudstyr til fast friformsfremstilling | |
| TWI799481B (zh) | 封阻型異氰酸酯 | |
| DK3405321T3 (da) | Formstøbningsfremgangsmåde | |
| MA43271A (fr) | Formulations améliorées de déférasirox et leurs procédés de fabrication | |
| DK3352950T3 (da) | Industrirobot | |
| DK3307216T3 (da) | Termoformbare halvstive ortoser | |
| DK3445553T3 (da) | Præformfremstillingsindretning | |
| DK3416923T3 (da) | Gipsplade | |
| MA50204A (fr) | Procédé de fabrication de feuilles absorbantes souples | |
| DK3429976T3 (da) | Gipsplade | |
| ES1174560Y (es) | Polea | |
| DK3368471T3 (da) | Vand-gas-skiftefremgangsmåde | |
| DK3502357T3 (da) | Hurtigskifter | |
| DK3436447T3 (da) | Isoquinolinyl-triazolon-komplekser | |
| MA43307A (fr) | Ligne de fabrication industrielle | |
| DK3559365T3 (da) | Gipsplade | |
| DK4029059T3 (da) | Fremstillingsfremgangsmåde | |
| DK3791095T3 (da) | Proceskomponent |